News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CureDuchenne Media Statement Regarding ProSensa Holding N.V. (RNA) Announcement Of Regulatory Path Forward For Drisapersen As A Potential Treatment For DMD


6/3/2014 10:01:49 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--CureDuchenne, a nonprofit that raises awareness and funds research to find a cure for Duchenne muscular dystrophy, issued the following statement today regarding the announcement by Prosensa Holding N.V. (NASDAQ: RNA) that the United States Food and Drug Administration (FDA) has outlined a regulatory path forward, under an accelerated approval pathway, for drisapersen, a potential treatment for Duchenne Muscular Dystrophy (DMD):

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES